TY - JOUR
T1 - Is host heparanase required for the rapid spread of heparan sulfate binding viruses?
AU - Khanna, Mayank
AU - Ranasinghe, Charani
AU - Browne, Anna M.
AU - Li, Jin Ping
AU - Vlodavsky, Israel
AU - Parish, Christopher R.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Vaccinia virus (VACV), like many other viruses, binds to cell surface heparan sulfate (HS) prior to infecting cells. Since HS is ubiquitously expressed extracellularly, it seemed likely that VACV-HS interaction may impede virus spread, with host heparanase, the only known mammalian endoglycosidase that can degrade HS, potentially overcoming this problem. In support of this hypothesis, we found that, compared to wild type, mice deficient in heparanase showed a 1–3 days delay in the spread of VACV to distant organs, such as ovaries, following intranasal inoculation, or to ovaries and spleen following intramuscular inoculation. These delays in spread occurred despite heparanase deficiency having no effect on VACV replication at inoculation sites. Subsequent in vitro studies revealed that heparanase treatment released VACV from HS expressing, but not HS deficient, infected cell monolayers. Collectively these data suggest that VACV relies on host heparanase to degrade HS in order to spread to distant sites.
AB - Vaccinia virus (VACV), like many other viruses, binds to cell surface heparan sulfate (HS) prior to infecting cells. Since HS is ubiquitously expressed extracellularly, it seemed likely that VACV-HS interaction may impede virus spread, with host heparanase, the only known mammalian endoglycosidase that can degrade HS, potentially overcoming this problem. In support of this hypothesis, we found that, compared to wild type, mice deficient in heparanase showed a 1–3 days delay in the spread of VACV to distant organs, such as ovaries, following intranasal inoculation, or to ovaries and spleen following intramuscular inoculation. These delays in spread occurred despite heparanase deficiency having no effect on VACV replication at inoculation sites. Subsequent in vitro studies revealed that heparanase treatment released VACV from HS expressing, but not HS deficient, infected cell monolayers. Collectively these data suggest that VACV relies on host heparanase to degrade HS in order to spread to distant sites.
KW - Heparan sulfate
KW - Heparanase
KW - Poxviruses
KW - Vaccinia virus
KW - Virus spread
UR - http://www.scopus.com/inward/record.url?scp=85060003656&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2019.01.001
DO - 10.1016/j.virol.2019.01.001
M3 - Article
SN - 0042-6822
VL - 529
SP - 1
EP - 6
JO - Virology
JF - Virology
ER -